Skip to search formSkip to main contentSkip to account menu

Smoothened Antagonist LDE225

Known as: LDE-225, LDE225, NVP-LDE225 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Biphenyl CompoundsPyridines
Smoothened Antagonist LDE225 Topical

Narrower (1)

sonidegib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
371 Background: Sonidegib (LDE225) is a potent, selective, and orally bioavailable inhibitor of smoothened receptor that… 
2016
2016
Exposure‐Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors
Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway‐dependent tumors, and has recently… 
2016
2016
Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid…
PurposeSonidegib prevents activation of the Hedgehog signal transduction pathway. This PK-QT analysis has been performed to test… 
Review
2015
Review
2015
Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
Background: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has been approved for the treatment of disease-related splenomegaly… 
2015
2015
Successful implementation of a novel trial model: The Signature program.
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
2015
2015
Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study
2013
2013
A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL SONIDEGIB (LDE225) VERSUS TEMOZOLOMIDE IN PATIENTS WITH HEDGEHOG PATHWAY-ACTIVATED RELAPSED…
2012
2012
Abstract 4818: The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Medulloblastoma (MB), an invasive primitive… 
2011
2011
Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms
Background:This study was designed to evaluate the role of the hedgehog pathway in tumor progression of murine islet cell tumors… 
2011
2011
Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation.
3062 Background: LDE225 is a potent and selective inhibitor of Smo, a key regulatory protein in the Hedgehog (Hh) signaling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)